Recombinant human nerve growth factor (rhNGF) is regarded as the most promising therapy for neurodegeneration of the central and peripheral nervous systems as well as for several other pathological conditions involving the immune system. However, rhNGF is not commercially available as a drug. In this work, we provide data about the production on a laboratory scale of large amounts of a rhNGF that was shown to possess in vivo biochemical, morphological, and pharmacological effects that are comparable with the murine NGF (mNGF), with no apparent side effects, such as allodynia. Our rhNGF was produced by using conventional recombinant DNA technologies combined with a biotechnological approach for high-density culture of mammalian cells, which yielded a production of Ϸ21.5 ؎ 2.9 mg͞liter recombinant protein.The rhNGF-producing cells were thoroughly characterized, and the purified rhNGF was shown to possess a specific activity comparable with that of the 2.5S mNGF by means of biochemical, immunological, and morphological in vitro studies. This work describes the production on a laboratory scale of high levels of a rhNGF with in vitro and, more important, in vivo biological activity equivalent to the native murine protein.mammalian cells ͉ miniPerm system ͉ neurotrophic activity R ecombinant proteins are promising for the treatment of many neurodegenerative and inflammatory diseases. Compelling basic and preclinical evidence points to neurotrophic and neurokine factors as potential candidates for preventing biochemical, pharmacological, and molecular deficits of several pathologies that lack effective therapies (reviewed in ref. 1). Some of these growth factors, including nerve growth factor (NGF) (2) have already been tested in preclinical and clinical trials. Indeed, murine NGF (mNGF) has been used successfully for human corneal and pressure ulcers (3-5), as well as vasculite (6) and crush syndrome (7), whereas recombinant human NGF (rhNGF) was shown to be effective in rodent and primate models of experimental allergic encephalomyelitis (8) and Alzheimer's disease (9, 10), as well in phase-II clinical trials of peripheral neuropathies (11). These findings are particularly interesting considering that NGF, which was identified originally as a potent neurotrophic factor for sympathetic and sensory neurons (12), was found to be essential also for basal forebrain cholinergic neurons (reviewed in ref. 13). Studies also showed that many other mammalian cells are NGF-responsive, including cells of the hemopoietic immune system (14), and, for some pathologies, symptoms also correlated with alterations of NGF serum levels (15, 16).All of this evidence supports the pharmacological interest for NGF as a useful therapeutic agent to promote the regression of many pathological conditions (1). However, the clinical efficacy of NGF has been obtained with the 2.5S mNGF (3-7), which cannot be used for human therapy on large scale. Therefore, for clinical trials and therapeutic purposes, large amounts of the recombinant human protein ...